Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HSTM vs SABA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HSTM Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

HSTM Overall Winner 6-Pillar Tally: HSTM 5 – 0 SABA (1 Tie) Matrix Metrics: HSTM 9 – 1 SABA

As of Nov 20, 2026, HealthStream Inc (HSTM) is the stronger overall head-to-head candidate over Saba Capital Income & Opportunities Fund II (SABA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSTM carries a Unified Composite Score of 50.5/100 (HOLD) at $26.29 (28.6x Forward P/E, 7.8% operating margin), whereas SABA carries 44.2/100 (HOLD) at $7.33 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: HSTM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 24.4); meanwhile SABA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HSTM vs SABA
HSTM NASDAQ Head-to-Head Winner
HealthStream Inc
Services-Computer Programming, Data Processing, Etc.
$26.29
+0.19% 1D
Market Cap $802.8M
TTM Revenue $328M
Forward P/E 28.6x
Beta / 30D Vol 0.38β · 44% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 24
RSI-14: 24.4 · SMA20: $30.26 · SMA50: $30.91
SABA NYSE
Saba Capital Income & Opportunities Fund II
Institutional Equity
$7.33
-0.27% 1D
Market Cap $251.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.37β · 13% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 38.0 Fund 55.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 30
RSI-14: 29.9 · SMA20: $7.56 · SMA50: $7.75

6-Pillar Scorecard Institutional Category Breakdown (HSTM 5 – 0 SABA)

Columns: Metric · HSTM · SABA
1. Valuation Multiples HSTM
Forward P/E 28.6x N/M
Trailing P/E 37.5x N/M
PEG Ratio 2.87x N/M
EV / Revenue 2.4x N/M
2. Growth & Scale HSTM
Revenue Growth (YoY) +8.9% N/A
Earnings Growth (YoY) -10.0% N/A
TTM Revenue (USD) $328M N/A
Market Cap $802.8M $251.8M
3. Profitability & Quality HSTM
Gross Margin 64.7% N/A
Operating Margin 7.8% N/A
Net Profit Margin 6.2% N/A
Return on Equity (ROE) 5.5% N/A
4. Balance Sheet & Cash Flow HSTM
Cash Generation (TTM) $45M EBITDA N/A
Cash Flow Margin 13.6% EBITDA Mgn N/A
Net Cash / Leverage $13.13 Book/Sh · 5.5% ROE N/A ROE
Dividend Yield 0.50% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 21.1% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat HSTM
OpEx & R&D Intensity 56.9% of Rev ($187M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HSTM (9) vs SABA (1)
Institutional Metric HSTM SABA Criterion Row Edge
Market Capitalization
Scale
$802.8M $251.8M Larger Scale HSTM
Trailing P/E Ratio
Valuation
37.5x N/M Lower Multiple HSTM
Forward P/E Ratio
Valuation
28.6x N/M Lower Multiple HSTM
Revenue Growth (YoY)
Growth
+8.9% N/A Higher Growth HSTM
Operating Margin (TTM)
Profitability
7.8% N/A Higher Margin HSTM
Net Profit Margin
Profitability
6.2% N/A Higher Margin HSTM
Return on Equity (ROE)
Capital Efficiency
5.5% N/A Higher ROE HSTM
52-Week Range Position
Momentum
42% ($20–$36) 4% ($7–$9) Stronger Trend HSTM
Beta / 30D Volatility
Risk Regime
0.38β · 44% Vol 0.37β · 13% Vol Lower Realized Risk SABA
Unified Institutional Score
Composite Signal
50.5 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite HSTM
Trailing 12M Revenue (USD)
Operating Scale
$328M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.87x PEG · 2.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$45M EBITDA ($13.13 Book/Sh · 5.5% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SABA +20.32 pp
HSTM: -24.0% · SABA: -3.68%
3M Horizon HSTM +1.85 pp
HSTM: -8.65% · SABA: -10.5%
6M Horizon HSTM +23.26 pp
HSTM: +10.42% · SABA: -12.84%
1Y Horizon HSTM +22.82 pp
HSTM: +6.78% · SABA: -16.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HSTM vs SABA. Trailing 12-month operating profitability (HSTM 7.8% vs SABA N/A) and valuation multiples (HSTM 28.6x vs SABA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HSTM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$328M
Gross Margin64.7%
Op. Margin7.8%
ROE / Fwd P/E5.5% · 28.6x
SABA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HSTM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HSTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SABA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SABA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HSTM Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $802.8M market capitalization and 7.8% operating margin.
OpEx & R&D Reinvestment 56.9% of Rev ($187M)
90D Engineering Disclosures 0 Published
SABA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $251.8M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HSTM vs SABA Key Questions & Quantitative Answers

As of Nov 20, 2026, HealthStream Inc (HSTM) is the stronger overall head-to-head candidate over Saba Capital Income & Opportunities Fund II (SABA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSTM carries a Unified Composite Score of 50.5/100 (HOLD) at $26.29 (28.6x Forward P/E, 7.8% operating margin), whereas SABA carries 44.2/100 (HOLD) at $7.33 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: HSTM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 24.4); meanwhile SABA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HSTM leads the Growth & Scale pillar: HSTM posts +8.9% YoY revenue growth and -10.0% YoY earnings growth on $328M TTM revenue (64.7% gross margin, 7.8% operating margin), compared with SABA at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HSTM generates $328M in USD-normalized revenue versus N/A for SABA. In operating R&D and SG&A reinvestment, HSTM deploys 56.9% of Rev ($187M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SABA.

HSTM screens cheaper on headline valuation multiples. HSTM trades at 28.6x Forward P/E, 37.5x Trailing P/E, 2.87x PEG, and 2.4x EV/Revenue (13.6% EBITDA margin), whereas SABA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HSTM (5.5% ROE) versus SABA (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, HSTM carries 21.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.38β · 44% Vol realized risk). By comparison, SABA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 13% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.